Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Fuseya, Takahiro ^a   Furuhashi, Masato ^a   Yuda, Satoshi ^a,b   Muranaka, Atsuko ^a   Kawamukai, Mina ^a   Mita, Tomohiro ^a   Ishimura, Shutaro ^a   Watanabe, Yuki ^a   Hoshina, Kyoko ^a   Tanaka, Marenao ^a   Ohno, Kohei ^a   Akasaka, Hiroshi ^a   Ohnishi, Hirofumi ^a   Yoshida, Hideaki ^a   Saitoh, Shigeyuki ^a,c   Shimamoto, Kazuaki ^c   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Clinical Laboratory Medicine ^*  (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adipokine; Fatty acid binding protein 4; Left ventricular diastolic dysfunction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; FATTY ACID BINDING PROTEIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DATA BASE; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; POPULATION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSIS; HEALTH SURVEY; HEART LEFT VENTRICLE FUNCTION; PROCEDURES;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84906840317     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0126-7     Document Type: Article

References (42)

1. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008, 7:489-503. 10.1038/nrd2589, 18511927.
2. Furuhashi M, Ishimura S, Ota H, Miura T. Lipid chaperones and metabolic inflammation. Int J Inflam 2011, 2011:642612. 10.4061/2011/642612, 22121495.
3. Iso T, Maeda K, Hanaoka H, Suga T, Goto K, Syamsunarno MR, Hishiki T, Nagahata Y, Matsui H, Arai M, Yamaguchi A, Abumrad NA, Sano M, Suematsu M, Endo K, Hotamisligil GS, Kurabayashi M. Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol 2013, 33:2549-2557. 10.1161/ATVBAHA.113.301588, 23968980.
4. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379. 10.1126/science.274.5291.1377, 8910278.
5. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705. 10.1038/89076, 11385507.
6. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008, 118:2640-2650. 18551191.
7. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965. 10.1038/nature05844, 17554340.
8. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413. 10.1373/clinchem.2005.062463, 16423904.
9. Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, Inouye K, Rickey LM, Ercal BC, Furuhashi M, Tuncman G, Hotamisligil GS. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013, 17:768-778. 10.1016/j.cmet.2013.04.012, 23663740.
10. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802. 10.1161/ATVBAHA.107.146274, 17510463.
11. Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, Fuseya T, Yamashita T, Tanaka M, Yoshida H, Shimamoto K, Miura T. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012, 25:1124-1130. 10.1038/ajh.2012.88, 22717543.
12. Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 2013, 8:e81318. 10.1371/journal.pone.0081318, 24278421.
13. Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010, 14:2223-2234. 10.1111/j.1582-4934.2010.01141.x, 20716126.
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
15. Roger VL. Epidemiology of heart failure. Circ Res 2013, 113:646-659. 10.1161/CIRCRESAHA.113.300268, 23989710.
16. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013, 6:279-286. 10.1161/CIRCHEARTFAILURE.112.972828, 23271790.
17. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J 2007, 153:907-917. 10.1016/j.ahj.2007.03.019, 17540190.
18. Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, Chiang SJ, Suzuki H, Ito C, Sato F, Watada H, Daida H. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2013, 12:38. 10.1186/1475-2840-12-38, 23446214.
19. Vural B, Atalar F, Ciftci C, Demirkan A, Susleyici-Duman B, Gunay D, Akpinar B, Sagbas E, Ozbek U, Buyukdevrim AS. Presence of fatty-acid-binding protein 4 expression in human epicardial adipose tissue in metabolic syndrome. Cardiovasc Pathol 2008, 17:392-398. 10.1016/j.carpath.2008.02.006, 18417367.
20. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009, 105:326-334. 10.1161/CIRCRESAHA.109.200501, 19608978.
21. Aragones G, Saavedra P, Heras M, Cabre A, Girona J, Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol 2012, 11:72. 10.1186/1475-2840-11-72, 22709426.
22. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991, 24:195-201. 10.1016/0009-9120(91)90571-U, 2040092.
23. Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002, 113:717-722. 10.1016/S0002-9343(02)01394-3, 12517360.
24. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470. 10.1136/hrt.2002.007005, 15020532.
25. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491. 10.1161/01.CIR.0000057810.48709.F6, 12654604.
26. Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H, Zhu W, Zhang J, Xu A, Wei M, Jia W. Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin Sci 2013, 124:115-122. 10.1042/CS20120004, 23013043.
27. Djousse L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS, Tracy RP, Mozaffarian D, Siscovick DS, Mukamal KJ, Zieman SJ. Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study. Eur J Heart Fail 2013, 15:394-399. 10.1093/eurjhf/hfs196, 23223158.
28. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241. 10.1056/NEJM199007263230405, 2195340.
29. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009, 121:227-252. 10.1016/j.pharmthera.2008.09.009.
30. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994. 10.2337/diabetes.48.10.1987, 10512363.
31. Engeli S, Utz W, Haufe S, Lamounier-Zepter V, Pofahl M, Traber J, Janke J, Luft FC, Boschmann M, Schulz-Menger J, Jordan J. Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women. Heart 2013, 99:944-948. 10.1136/heartjnl-2013-303735, 23598540.
32. Balci MM, Arslan U, Firat H, Kocaoglu I, Vural MG, Balci KG, Maden O, Gurbuz OA, Ardic S, Yeter E. Serum levels of adipocyte fatty acid-binding protein are independently associated with left ventricular mass and myocardial performance index in obstructive sleep apnea syndrome. J Investig Med 2012, 60:1020-1026. 22918198.
33. Cabre A, Valdovinos P, Lazaro I, Bonet G, Bardaji A, Masana L. Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. Cardiovasc Diabetol 2013, 12:72. 10.1186/1475-2840-12-72, 23642261.
34. Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS. Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol 2013, 12:105. 10.1186/1475-2840-12-105, 23866022.
35. Baessler A, Lamounier-Zepter V, Fenk S, Strack C, Lahmann C, Loew T, Schmitz G, Bluher M, Bornstein SR, Fischer M. Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects. Nutr Diabetes 2014, 4:e106. 10.1038/nutd.2014.3, 24513579.
36. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 2006, 103:10741-10746. 10.1073/pnas.0603509103, 16818881.
37. Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One 2011, 6:e27356. 10.1371/journal.pone.0027356, 22102888.
38. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol 2012, 32:2327-2335. 10.1161/ATVBAHA.112.248609.
39. Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, Lo SV, Tse HF, Woo YC, Yeung CY, Cheung BM, Lam KS. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc 2013, 2:e004176. 10.1161/JAHA.112.004176, 23525430.
40. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Lichnovska R, Janout V. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007, 37:637-642. 10.1111/j.1365-2362.2007.01835.x, 17635574.
41. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2011, 26:408-413. 10.1007/s00380-010-0060-x, 21063874.
42. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-158. 10.1016/j.atherosclerosis.2007.04.045, 17553506.